PVS – Earnings Review – [BUY] – 3Q25: Profit growth in line with expectations
∙ 3Q25 revenue grew by 99% yoy, and NPAT grew 73% yoy
∙ Net financial gains drove 3Q25 NPAT growth
∙ 4Q25F: Staying busy, with triple-digit NPAT growth expected
Featured Analysis
SBV ramps up repo injections
Derivatives: A reversal pattern?
Market commentary: Divergent movements
Chart of the day: Short-term sell signal?
SIP – Brief – [NONRATED] – Surging expenses dragged the 1Q26 net profit
Derivatives: Mounting selling pressure
Market commentary: Selling pressure persists
